The pharmaceutical trade increased by $116.6 billion in 2017

Yesterday, the China Medical and Health Products Import and Export Chamber of Commerce announced the situation of China's pharmaceutical and health care products exports in 2017, saying that China's import and export of medical and health care products amounted to US$116.676 billion, up 12.64 percent year-on-year.
, however, in the growing situation, China's pharmaceutical trade encountered a significant increase in the number of trade frictions, a new round of international industrial competition more intense, some emerging economies, such as the decline in payment capacity and other adverse factors. At the same time, the global economy as a whole showed a recovery, the international market demand for pharmaceutical trade stabilized and rebounded, China's pharmaceutical export structure was further optimized, the pace of internationalization of enterprises accelerated, new development momentum is taking shape, and the overall development situation of pharmaceutical trade is improving.
2017, China's imports and exports of medical and health care products amounted to US$116.676 billion, up 12.64 percent year-on-year, according to customs statistics. Of this total, exports amounted to US$60,799 million, reversing last year's decline by 9.44 per cent, the highest growth rate in nearly five years, with imports of US$55,877 million, an increase of 16.34 per cent, and a foreign trade surplus of US$4,922 million, a decrease of 34.60 per cent. Overall, in 2017, international market demand rose, China's supply reform began to bear fruit, pharmaceutical exports increased prices, exports increased steadily, while domestic demand remained at a high level and imports maintained rapid growth.
According to the China Medical and Health Products Import and Export Chamber of Commerce, in 2017 China's pharmaceutical exports rebounded, with exports amounting to US$3.640 billion, up 2.07% YoY, the vegetable extract market was active, exports amounted to US$2.010 billion, up 4.33% YoY, and Chinese traditional medicine exports increased by US$250 million, up 11.03% YoY, while Chinese medicine and beverage exports continued to grow by 2.3% YoY.
, Western medicine exports also rebounded significantly. In 2017, China's exports of Western pharmaceutical products increased by 12.62 percent to US$35,456 million. Among them, API exports were US$29.117 billion, up 13.71% Year-on-Year. The rising cost of environmental protection of API enterprises has led to the contraction of supply side and the gradual withdrawal of backward production capacity, and the competitive landscape of high-quality enterprises has continued to improve. Production exports were $3.456 billion, up 8.32% year-on-year.
Medical device exports continued to grow steadily, with medical device exports amounting to US$21.703 billion in 2017, up 5.84% YoY, of which medical dressings, disposable consumables, diagnostic and therapeutic equipment, health care and rehabilitation equipment, and dental equipment all achieved steady growth of 2.97%, 9.53%, 4.11%, 6.29% and 17.00%, respectively.
In 2017, imports of medicines continued to show double-digit growth, reaching US$55,877 million, up 16.34% YoY. With the "priority review" system officially landing in China, imported drugs began to pile into the Chinese market.
in 2017 biomedicine, in-body diagnosis and other new areas, China's medical and health products import and export Chamber of Commerce is considered to be on the rise. China's biopharmaceutical industry has been growing steadily, with an average annual growth rate of more than 15%. China has become the second largest country after the United States, with the largest number of biological drugs under study. China's in-body diagnostic reagent market is also expanding, with a market size of 72.3 billion yuan and a compound annual growth rate of 18.7% by 2019.
in the overall export situation, with the strong growth momentum of trade in medical services, trade friction is gradually increasing. For local enterprises in China, with the continuous extension and segmentation of the pharmaceutical industry chain, CRO (pharmaceutical research and development contract outsourcing services), CMO (pharmaceutical production contract outsourcing services), CSO (pharmaceutical sales contract outsourcing services) and other new industries are gradually emerging, becoming a new form of Chinese pharmaceutical enterprises to participate in the international division of labor. Chinese medicine services to speed up the "going out" pace. Data show that China sends about 2,000 Chinese medicine clinicians each year, accounting for 60% of the total number of expatriate medical workers. More than 60 Chinese medicine service trade organizations in more than 20 countries and regions to open Chinese medicine hospitals, Chinese medicine clinics, Chinese medicine health care institutions, Chinese medicine research centers, etc. , the annual number of visits reached 250,000.
Zhang Wei, deputy director of the Legal General Department of the China Medical and Health Products Import and Export Chamber of Commerce, said that there has been a marked increase in intellectual property cases in the frequency of trade relief cases against China. In recent years, China's pharmaceutical industry has experienced a clear upward trend in trade friction, in 2017, China's exports of pharmaceutical products encountered 15 trade friction investigations. These include five anti-dumping investigations and one anti-circumvention investigation initiated by India, four IP infringement investigations and one antitrust lawsuit initiated by the United States, as well as two anti-dumping investigations initiated by the European Union and one anti-dumping investigation initiated by Ukraine.
understood that in the past, Chinese enterprises in patent litigation experience is few, few successful cases, and now, enterprises gradually improve the awareness of intellectual property rights, the use of legal weapons to protect their ability to significantly improve. In 2017, two patent lawsuits by Chinese pharmaceutical companies were won. In June, Huahai Pharmaceuticals and its U.S. subsidiary, Princeton, won a patent challenge to Noven's Brisdelle Parostin capsule. This is the first time that a Chinese pharmaceutical company has stated the success story of the ANDA Challenge in paragraph 4 (PIV). In December, Greenlee Pharmaceuticals won a one-day patent infringement lawsuit against Kabalatin in Germany, and the court upheld a first-instance judgment that Kabaratin's one-day patch did not infringe the patent rights regardless of the validity of Novarma's original patent.
Regarding the basic trend of internationalization of the medical and health industry in 2018, the China Medical and Health Products Import and Export Chamber of Commerce believes that due to the current ability of Chinese pharmaceutical enterprises in international registration and certification, research and development, international marketing, global resource mix and other aspects continue to improve, pharmaceutical export product patterns and market patterns are changing in depth, the international trade environment for medicine is generally improving.
Among them, favorable factors are: the United States, the European Union, India and other major market demand recovery and is expected to maintain stable growth, preparations, medical equipment and other products exports to the European and American markets significantly accelerated, bulk API, medical device products in the global pharmaceutical market rigid demand has not changed, export volume and prices are gradually with the global economic recovery and recovery.
, South America, Africa and other market uncertainties still exist, the impact of pharmaceutical trade friction can not be ignored. With the implementation of the "13th Five-Year Plan" api industry plan, China's pharmaceutical industry will be more orderly, more high-tech content, environmental protection, resource conservation, increase added value, to the downstream extension of the direction of development, more conducive to the continuous optimization and upgrading of export structure. It is expected that the fundamentals of the steady development of pharmaceutical foreign trade will continue to be maintained in 2018. (Economic Watch Network)